ImmunityBio Inc [NASDAQ: IBRX] stock went on a downward path that fall over -5.52% on Tuesday, amounting to a one-week price increase of more than 1.11%.
Over the last 12 months, IBRX stock rose by 7.03%. The one-year ImmunityBio Inc stock forecast points to a potential upside of 75.96. The average equity rating for IBRX stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.42 billion, with 853.39 million shares outstanding and 91.82 million shares in the current float. Compared to the average trading volume of 8.98M shares, IBRX stock reached a trading volume of 6744213 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $11.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 20, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 06, 2025, representing the official price target for ImmunityBio Inc stock. Previously, the target price had yet another raise to $6, while BTIG Research analysts kept a Buy rating on IBRX stock. On May 12, 2023, analysts decreased their price target for IBRX shares from 10 to 4.
IBRX Stock Performance Analysis:
ImmunityBio Inc [IBRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.11. With this latest performance, IBRX shares dropped by -14.11% in over the last four-week period, additionally plugging by 13.22% over the last 6 months – not to mention a rise of 7.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 47.75, with the RSI for the last a single of trading hit 0.19, and the three-weeks RSI is set at 0.20 for ImmunityBio Inc [IBRX]. The present Moving Average for the last 50 days of trading for this stock 2.71, while it was recorded at 2.82 for the last single week of trading, and 3.29 for the last 200 days.
Insight into ImmunityBio Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ImmunityBio Inc [IBRX] shares currently have an operating margin of -1003.83% and a Gross Margin at 45.92%. ImmunityBio Inc’s Net Margin is presently recorded at -1310.30%.
Return on Equity for this stock declined to -116.15%, with Return on Assets sitting at -116.15%.
ImmunityBio Inc [IBRX] Institutonal Ownership Details
There are presently around $9.24%, or 35.68% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0135%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1448%.
